Real-World Comparative Effectiveness of First-Line Alectinib Versus Crizotinib in Patients With Advanced ALK-Positive NSCLC With or Without Baseline Central Nervous System Metastases
- Resource Type
- Article
- Source
- In
JTO Clinical and Research Reports April 2023 4(4) - Subject
- Language
- ISSN
- 2666-3643